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Adjuvants contribute to enhancing and shaping the vaccine immune response through 
different modes of action. Here early biomarkers of adjuvanticity after primary immu-
nization were investigated using four different adjuvants combined with the chimeric 
tuberculosis vaccine antigen H56. C57BL/6 mice were immunized by the subcutaneous 
route with different vaccine formulations, and the modulation of primary CD4+ T cell and 
B cell responses was assessed within draining lymph nodes, blood, and spleen, 7 and 
12 days after priming. Vaccine formulations containing the liposome system CAF01 or 
a squalene-based oil-in-water emulsion (o/w squalene), but not aluminum hydroxide 
(alum) or CpG ODN 1826, elicited a significant primary antigen-specific CD4+ T cell 
response compared to antigen alone, 7 days after immunization. The effector function 
of activated CD4+ T cells was skewed toward a Th1/Th17 response by CAF01, while 
a Th1/Th2 response was elicited by o/w squalene. Differentiation of B cells in short-
lived plasma cells, and subsequent early H56-specific IgG secretion, was observed in 
mice immunized with o/w squalene or CpG adjuvants. Tested adjuvants promoted the 
germinal center reaction with different magnitude. These results show that the immuno-
logical activity of different adjuvants can be characterized by profiling early immunization 
biomarkers after primary immunization. These data and this approach could give an 
important contribution to the rational development of heterologous prime–boost vaccine 
immunization protocols.
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inTrODUcTiOn
Adjuvants are key components in the vaccine formulations since they provide the necessary help 
for enhancing and shaping the vaccine immune responses. Although vaccine adjuvant research 
was at first based on empirical approaches, the new insights into the immunological mechanisms 
involved in the vaccination response have now allowed the improvement of knowledge in the mode 
of action of various compounds. This is particularly due to the intriguing role of the innate response, 
together with the development of novel technical tools. Among the priorities on the innovations to 
boost research in the field of vaccine is the generation of a toolbox of adjuvants, with a well-defined 
profile to shape the immune response, which can be applied to vaccines against diverse pathogens 
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(www.iprove-roadmap.eu) (1). New adjuvants are also needed 
to improve existing vaccines in different population groups for 
which the activity of current adjuvants may differ. These include 
the elderly, infants, and chronically infected subjects that mount 
a suboptimal immune response to vaccination (2–4). Profiling 
the mode of action of different adjuvants is of critical importance 
for the rationale design of vaccination strategies, based on heter-
ologous combinations of vaccine formulations for priming and 
boosting (5–8).
According to their mechanism of action, adjuvants are com-
monly classified as immunomodulatory molecules, delivery 
systems, or a combination of both (9). Immunomodulatory 
molecules mainly activate the innate immune receptors, such as 
TLRs, NOD-like receptors, C-type lectins, and RIG-I-like recep-
tors, generating signals that determine the proper activation 
of downstream adaptive immune responses and cells homing. 
The nature of the initial “danger” signals perceived by innate 
immune cells can dictate the type, quality, and magnitude of the 
adaptive immune response. This offers unique opportunities to 
custom tailor new classes of adjuvants to generate desired types 
of immune response. Delivery systems – such as mineral salts, 
liposomes, microparticles, saponins, and emulsions – improve 
the delivery and presentation of the vaccine to the immune 
system (9). Combination adjuvants include more components 
that act synergistically by activating a variety of immune 
mechanisms (10).
The immunological signature of adjuvants is generally estab-
lished at the end of immunization schedules including booster 
immunizations (11, 12), and secondary immune responses 
are analyzed to compare their adjuvanticity or describe novel 
potential adjuvant molecules. Within the ADITEC project (13), 
a unique effort has been conducted to compare head to head 
the mechanism of action and efficacy of five different adjuvants, 
combined with vaccine antigens from Mycobacterium tuber-
culosis, influenza, and Chlamydia (14). Nevertheless, when a 
vaccine formulation is injected into the host, the first influence 
on the magnitude, type, and quality of the downstream immune 
response, including the generation of memory, is elicited at 
the priming event. For this reason, the characterization of the 
adjuvant properties of a vaccine formulation at an early time 
point during the primary response is of critical importance 
for the rationale design of vaccination strategies and optimal 
prime–boost combinations.
The primary response to vaccination takes place locally, within 
the draining lymph nodes, where the antigen-presenting cells 
present the vaccine antigen to specific CD4+ T cells that proliferate 
and differentiate into various functionally defined subset effector 
cells (15). One of these subtypes is T follicular helper (Tfh) cells 
that relocate to B–T cell borders and interfollicular regions (16, 
17). They are specialized in regulating multiple stages of antigen-
specific B-cell immunity and triggering their differentiation into 
long-lived plasma cells (PCs) or memory B cells. In the extra-
follicular reaction, some antigen-primed B cells, after cognate 
contact of Tfh cells, undergo a process of rapid differentiation in 
short-lived PC. As a result, they produce low affinity antibodies, 
such as IgM and IgG, which appear in serum at low concentration 
a few days after immunization, and undergo apoptosis after a few 
days of intensive antibody secretion (16, 18). Interaction of Tfh 
cells with B cells also drives the germinal center (GC) reaction, a 
dynamic microanatomical structure that supports the generation 
of B-cell activation, antibody class switch recombination, and 
affinity maturation (17, 19). T-cell priming is therefore an essen-
tial event for the induction of the adaptive immune response to 
vaccination, and it represents a key step in the vaccination process 
due to the close relationship with long-term humoral immunity 
and protective antibodies (18).
T-cell priming is influenced by the type of vaccine formula-
tion (antigen, adjuvant, delivery system), the dose, and the 
route of administration (20). We have recently demonstrated 
that the subcutaneous (SC) route was particularly efficient in 
priming antigen-specific CD4+ T cells capable of respond-
ing to booster immunization, whereas the T-cell response 
induced after nasal priming was poorly responsive to recall 
immunization (7). The modulation of CD4+ T cell priming 
has been characterized for bacterial delivery systems (21–23) 
and adjuvants, such as alum (24), lipopolysaccharide (25), or 
its derivative-like monophosphoril lipid A (26), cholera toxin 
(27), or its B subunit (CTB) (28, 29), CpG ODN (30), and 
the liposomal system CAF01 (7, 31). Different adjuvants have 
demonstrated the ability to induce Tfh cell differentiation 
(31–33). We have also exploited mathematical models as a 
tool to estimate in vivo the probability of antigen-specific CD4+ 
T cell expansion and dissemination upon immunization with 
adjuvanted vaccine formulations (34, 35).
In the present manuscript, in order to define early biomarkers 
of adjuvanticity, we have characterized the primary CD4+ T and B 
cell immune responses specific for the chimeric tuberculosis vac-
cine antigen H56 (36), elicited by four different adjuvants, alum, 
a squalene-based oil-in-water emulsion, CpG ODN 1826 (37), 
or the liposome system CAF01 (38). Our results show how dif-
ferent adjuvants modulate the acquired immune response to the 
vaccine antigen since the primary immunization, and highlight 
CD4+ T and B cell priming events as critical early biomarkers of 
adjuvanticity of different classes of molecules.
MaTerials anD MeThODs
Mice
Seven-week-old female C57BL/6 mice, purchased from Charles 
River (Lecco, Italy) were housed under specific pathogen-free 
conditions in the animal facility of the Laboratory of Molecular 
Microbiology and Biotechnology (LA.M.M.B.), Department 
of Medical Biotechnologies at University of Siena, and treated 
according to national guidelines (Decreto Legislativo 26/2014). 
All animal studies were approved by the Italian Ministry of Health 
with authorization n° 1004/2015-PR on 22 September, 2015.
adjuvants and immunizations
CAF01 [250  μg dimethyldioctadecylammonium (DDA) and 
50 μg trehalose dibehenate (TDB)/mouse; Statens Serum Institut, 
Denmark], CpG ODN 1826 (hereafter CpG, 20  μg/mouse; 
Eurofins MWG Operon, Germany), AddaVax squalene-based 
oil-in-water adjuvant [hereafter o/w squalene, 50  μl/mouse, 
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sorbitan trioleate (0.5% w/v) in squalene oil (5% v/v), and 
Tween 80 (0.5% w/v) in sodium citrate buffer (10  mM, pH 
6.5), Invivogen, USA], or aluminum hydroxide (hereafter alum, 
0.5  mg/mouse; 2% alhydrogel, Brenntag Biosector, Denmark) 
were mixed with H56 antigen (2  μg/mouse; Statens Serum 
Institut, Denmark). Vaccine formulations were subcutaneously 
injected, at the base of the tail, in a volume of 150 μl/mouse of 
10 mM Tris for CAF01, of 100 μl/mouse of PBS for CpG, and 
o/w squalene adjuvants or distilled water for alum. Control mice 
received 2 μg of H56 alone in 100 μl/mouse of PBS, while naïve 
mice were left as negative control. Mice were immunized at day 
0 and sacrificed on days 7 and 12.
sample collection and cell Preparation
Draining lymph nodes (sub iliac, medial, and external) and 
spleens were collected 7 and 12 days after priming. Samples were 
mashed onto 70-μm nylon screens (Sefar Italia, Italy) and washed 
two times in complete medium [RPMI medium (Lonza, Belgium) 
supplemented with 100  U/ml penicillin/streptomycin and 10% 
fetal bovine serum (Gibco, USA)]. Samples were treated with red 
blood cells lysis buffer according to the manufacturer’s instruc-
tion (eBioscience, CA, USA). Blood samples were taken on days 
7 and 12. Samples were incubated for 30 min at 37°C, centrifuged 
at 1200 × g at 4°C for 10 min, and sera were then collected and 
stored at −80°C until analysis.
Flow cytometric analysis and intracellular 
cytokine staining
Samples were incubated for 30 min at 4°C in Fc-blocking solution 
[complete medium with 5 μg/ml of CD16/CD32 mAb (clone 93; 
eBioscience, CA, USA)]. To evaluate tetramer-specific CD4+ 
T cells and follicular T cells in draining lymph nodes, cells were 
stained for 1 h at RT with PE-conjugated I-A(b) M. tuberculosis 
Ag85B precursor 280–294 (FQDAYNAAGGHNAVF) tetramer 
(kindly provided by NIH MHC Tetramer Core Facility, Emory 
University, Atlanta, GA, USA) together with BV650-conjugated 
anti-CXCR5 (clone 2G8, BD Biosciences, USA). Cells were 
washed and surface stained with HV500-conjugated anti-CD4 
(clone RM4-5; BD Biosciences), APC-conjugated anti-CD44 
(clone IM-7; Biolegend), BV786-conjugated anti-CD273 (PD-1, 
clone TY25; BD Biosciences). GC B cells were detected by stain-
ing with PE-conjugated anti-CD45R (anti-B220, clone RA3-6B2; 
BD Biosciences), BV421-conjugated anti-GL-7 (clone GL-7; 
BD Biosciences), PerCP e-Fluor 710-conjugated anti-CD95 
(clone 15A7; eBioscience). PCs were evaluated by staining with 
AF700-conjugated anti-CD45R (B220, clone 15A7; eBioscience), 
BV605-conjugated anti-IgD (clone 11-26C.2A; BD Biosciences), 
BV421-conjugated anti-CD138 (clone 281-2; BD Biosciences). 
Samples were labeled with LIVE/DEAD Fixable Near IR Dead Cell 
Stain Kit according to the manufacturer’s instruction (Invitrogen, 
USA). Intracellular staining for PE-CF594-conjugated anti-Bcl-6 
(clone K112-91, BD Biosciences) was performed using the FoxP3 
staining buffer set (eBioscience) according to the manufacturer’s 
instruction. Intracellular cytokine production was assessed 
on splenocytes cultured for 6  h in the presence of anti-CD28, 
anti-CD49d (both 2 μg/ml, eBioscience), and H56 protein (2 μg/
ml), or stimulated with PMA and ionomycin calcium salt (50 ng/
ml and 1 μM, respectively, Sigma-Aldrich) for positive control. 
Brefeldin A (BFA, 5 μg/ml, Sigma-Aldrich) and monensin solu-
tion (eBioscience) were added for the last 4 h of incubation. Cells 
were washed twice in PBS and then labeled with LIVE/DEAD 
Fixable Yellow Dead Cell Stain Kit according to the manufacturer’s 
instruction (Invitrogen, USA). Fixation and permeabilization 
were performed using BD Cytofix/Cytoperm kit according to the 
manufacturer’s instruction (BD Biosciences) before Fc-blocking 
and staining with HV500-conjugated anti-CD4 (clone RM4-5; 
BD Biosciences), APC-conjugated anti-CD44 (clone IM-7; 
Biolegend), PerCP Cy5.5-conjugated anti-IFN-γ (clone XMG1.2; 
BD Biosciences), PE-conjugated anti-IL-2 (clone JES6-5H4; BD 
Biosciences), AF700-conjugated anti-TNF-α (clone MP6-XT22; 
BD Biosciences), APC-conjugated anti-IL-17A (clone eBio17B7; 
eBioscience), AF488-conjugated anti-IL-4 (clone 11B11; eBiosci-
ence), and AF488-conjugated anti-IL-13 (clone eBio13A; eBiosci-
ence). Antibodies and tetramer were titrated for optimal dilution. 
About 5–10 ×  105 cells were stored for each sample acquired 
on LSR-II flow cytometer (BD Biosciences). Data analysis was 
performed using FlowJo (TreeStar, USA).
Multiplex cytokine assay
IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12p40, 
IL-12p70, IL-13, IL-17A, eotaxin, G-CSF, GM-CSF, IFN-γ, KC, 
MCP-1, MIP-1α, MIP-1β, RANTES, and TNF-α production 
were assessed in culture supernatants of restimulated splenocytes 
by Luminex immunoassay (BioRad, USA). Splenocytes were 
cultured with 2 μg/ml of H56 in complete medium for 72 h at 
37°C in 5% CO2, supernatants were then collected, and stored 
at −80°C. Analytes were detected using the multiplex cytokine 
immunoassay (Bio-Plex, BioRad) following the manufacturer’s 
protocol and analyzed by Bio-Plex Magpix Multiplex Reader 
(BioRad). Cytokine concentrations were expressed as picograms 
per milliliter and were calculated based on standard curve data 
using Bio-Plex Manager 6.1.
enzyme-linked immunosorbent assay
Serum H56-specific IgG, IgG1, and IgG2c were determined by 
enzyme-linked immunosorbent assay (ELISA). Flat-bottomed 
Maxisorp microtiter plates (Nunc, Denmark) were coated with 
H56 (0.5 μg/ml) for 3 h at 37°C and overnight at 4°C in a volume 
of 100 μl/well. Plates were washed and blocked with 200 μl/well of 
PBS with 1% BSA (Sigma-Aldrich) for 2 h at 37°C. Serum samples 
were added and titrated in twofold dilution in duplicate in PBS 
with 0.05% Tween 20 and 0.1% BSA (diluent buffer) in 100 μl/well. 
After incubation for 2 h at 37°C, samples were incubated with 
the alkaline phosphatase-conjugate goat anti-mouse IgG, IgG1, 
and IgG2c (each diluted 1:1000, Southern Biotechnology, USA) 
for 2 h at 37°C in 100 μl/well and developed by adding 1 mg/ml 
of alkaline phosphatase substrate (Sigma-Aldrich) in 200 μl/well. 
The optical density was recorded using Multiskan FC Microplate 
Photometer (Thermo Scientific). Antibody titers were expressed 
as the reciprocal of the highest dilution with an OD value ≥0.2, 
after background subtraction.
FigUre 1 | induction of ag85B-specific cD4+ T cells. C57BL/6 mice were subcutaneously immunized with H56 alone (H56) or combined with different 
adjuvants (o/w squalene, CAF01, alum, and CpG), and lymph nodes draining the site of immunization (dLN) were collected 7 days after immunization. Ag-specific 
T cells were identified by staining with Ag85B-specific MHC class II tetramers (Tet-Ag85B). (a) Tetramer+ T cells, detected as CD44high Tet-Ag85B+ cells, gated on 
live CD4+ lymphocytes, are shown from a single animal representative of the group. (B,c) Frequencies of Tetramer+ CD44+ T cells, with respect to CD4+ cells (B) 
and absolute numbers of Tetramer+ CD44+ T cells per dLN (c) elicited by different vaccine formulations, reported as mean ± SD of 8–10 mice per group, from 2 
independent experiments. Mann–Whitney test with Bonferroni correction for multiple pairwise comparisons was used for assessing statistical difference between 
each group immunized with adjuvant and the H56-immunized group. Kruskal–Wallis test, followed by Dunn’s post test for multiple comparisons, was used to assess 
the statistical difference between groups immunized with different adjuvants (*P ≤ 0.05).
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statistical analysis
Mann–Whitney test with Bonferroni correction for multiple 
pairwise comparisons was used for assessing statistical difference 
between each group immunized with adjuvant and the H56-
immunized group. The Kruskal–Wallis test, followed by Dunn’s 
post test for multiple comparisons, was used to assess statistical 
difference between groups immunized with different adjuvants 
A P value ≤ 0.05 was considered significant. Statistical analysis 
was performed using Graph Pad Prism version 6 (GraphPad 
Software, CA, USA).
resUlTs
The chimeric tuberculosis vaccine antigen H56 was combined 
with an o/w squalene-based emulsion, the liposome system 
CAF01, alum, or CpG and parenterally administered to 
mice in order to identify early biomarkers of adjuvanticity. 
The  activity of the different adjuvants when combined with 
H56 was assessed by analyzing the primary T CD4+ and B cell 
responses within the local draining lymph nodes, blood, and 
spleen. Primary T-cell response was characterized in terms of 
antigen-specific CD4+ T cell expansion and cytokine secre-
tion, while the mechanisms through which different adjuvants 
enhance B cell response were investigated by assessing PCs 
generation within draining lymph nodes and IgG antibodies 
release in blood, as well as analyzing the GC reaction within 
draining lymph nodes.
Primary ag-specific cD4+ T cell 
expansion and effector Function
The induction of antigen-specific CD4+ T cell expansion into the 
iliac draining lymph nodes was assessed 7 days after SC immuniza-
tion with the H56 vaccine antigen alone or combined with the dif-
ferent adjuvants. CD4+ T cells specific for the immunodominant 
FigUre 2 | intracellular cytokines production.  
(Continued)
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TaBle 1 | ratio of cytokine or chemokine production between 
formulations including adjuvants and antigen alone.
o/w squalene caF01 alum cpg
GM-CSF 0.5 11 1 0.4
IFN-γ 2 168 2.8 1.5
IL-12p40 0.5 3 1.4 2
Il-6 1.2 6 1.1 0.2
IL-17A 2.7 604 2.1 1.7
IL-3 0.4 3.6 1.1 0.17
Eotaxin 0.3 1.7 1.2 1.2
IL-5 0.1 0.07 0.2 0.01
IL-10 0.2 0.8 0.6 0.3
IL-13 0.1 0.8 0.4 0.03
MCP-1 0.4 0.17 1.1 0.16
MIP-1α 0.3 0.9 0.6 0.4
MIP-1β 0.2 0.4 0.7 0.2
The H56-specific cytokine and chemokine production was assessed in mice immunized 
with formulations containing adjuvants (o/w squalene, CAF01, alum, or CpG) or antigen 
H56 alone, by Luminex immunoassay. The ratio between the cytokine or chemokine 
concentrations detected in samples from mice immunized with adjuvants respect to 
antigen alone is reported. Filled squares indicate an increase (dark gray) or decrease 
(light gray) of at least threefolds.
C57BL/6 mice were subcutaneously immunized with H56 alone (H56) or combined with different adjuvants (o/w squalene, CAF01, alum, and CpG), and spleens 
were collected 7 days after immunization. Splenocytes were cultured for 6 h in the presence of anti-CD28, anti-CD49d, and H56 protein. (a) Dot plots showing the 
production of TNF-α, IFN-γ, IL-17, IL-4/IL-13 versus IL-2 assessed on live CD4+ CD44+ lymphocytes in each group. (B) Percentages of T cells positive for both IL-2 
and the indicated cytokines, with respect to total CD4+ CD44+ cells, elicited by different vaccine formulations. Data are reported as mean ± SD of five mice per 
group. Mann–Whitney test with Bonferroni correction for multiple pairwise comparisons was used for assessing statistical difference between each group immunized 
with adjuvant and the H56-immunized group. Kruskal–Wallis test, followed by Dunn’s post test for multiple comparisons, was used to assess the statistical difference 
between groups immunized with different adjuvants (*P ≤ 0.05).
FigUre 2 | continued
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epitope of Ag85B, that is part of the chimeric H56 protein, were 
identified using Ag85B280–294-complexed MHC class II tetramers. 
Staining specificity was determined using a control tetramer 
complexed with an unrelated antigen, which showed a level of 
staining below 0.02% (data not shown).
Representative dot plots showing the frequencies of tetramer-
positive (Tet+) T cells elicited by the different vaccine formula-
tions are shown in Figure 1A. Priming with o/w squalene and 
CAF01 elicited a significant increase of Tet+ T cells, both in terms 
of frequency with respect to total CD4+ T cells and absolute num-
ber, compared to the group immunized with H56 antigen alone 
(Figures  1B,C), while vaccine formulations containing alum 
and CpG did not elicit a significant primary T helper response 
(Figures 1B,C). Comparison between different adjuvants indi-
cated that immunization with CAF01 elicited a significant higher 
Ag-specific CD4+ T cell response compared to CpG and alum 
(Figure 1B). The analysis of percentage of Tet+ T cells elicited by 
the different vaccine formulations, repeated 12 days after prim-
ing, showed reduced frequencies in all groups (data not shown), 
suggesting that day 7 is a better time point for the analysis of 
antigen-specific T cell expansion in draining lymph nodes.
Since activated T helper cells exit the lymph nodes to recir-
culate, the effector function of H56-specific CD4+ T cells was 
assessed in splenocytes by flow cytometric analysis of intracel-
lular cytokine production elicited by antigen restimulation. 
Figure 2A reports representative dot plots of the different groups 
showing the frequencies of H56-specific CD4+ T cells produc-
ing TNF-α, IFN-γ, IL-17, or IL-4/IL-13 cytokines versus IL-2, a 
cytokine indicative of the proliferative response and activation 
program of antigen-specific T cells. In all groups, IL-2 was 
always co-expressed with one of the other cytokines especially 
with TNF-α, as clearly shown in Figure 2A. CAF01 induced the 
overall highest recall response upon antigen restimulation, with 
significant percentages of cells expressing TNF-α/IL-2 (21% of 
CD4+ CD44+ T cells), IFN-γ/IL-2 (12%), and IL-17/IL-2 (4%) 
with respect to H56-immunized mice and also toward CpG and 
alum (Figure  2B; P ≤  0.05). Vaccine formulation containing 
o/w squalene induced also a significant increase of TNF-α/IL-2 
(5%) and IFN-γ/IL-2 (1.2%) producing cells compared to H56-
immunized mice, together with a subpopulation of cells releas-
ing IL-4/IL-13 (0.8%), indicative of a mixed Th1/Th2 response 
(Figure 2B). Cytokine production was not observed in groups 
immunized with alum and CpG adjuvants, while administration 
of the H56 antigen alone stimulated the release of IL-4/IL-13 
(Figure 2B).
The levels of secreted cytokines upon a longer period of 
antigen restimulation (72 h) were measured by multiplex assay, 
including 22 different cytokines/chemokines. Concentrations 
of all soluble factors, measured in each tested group, are 
reported in Table S1 in Supplementary Material. In Table 1 and 
Figure 3 are reported the concentration and the fold change of 
the 13 cytokines and chemokines that were modulated by the 
tested adjuvants with at least a threefold change with respect to 
antigen alone.
The strongest modulatory effect was observed in the pres-
ence of CAF01, which induced a high increase of the cytokines 
GM-CSF, IFN-γ, IL-12p40, IL-6, IL-17A, and IL-3 with respect 
to the antigen alone (Figure 3; Table 1). O/w squalene and CpG 
were similar in eliciting a decrease of IL-5, IL-10, IL-13, and MIP-
1β (Figure 3; Table 1). Alum showed a poor modulatory effect 
with respect to antigen alone, except for IL-5 that was the only 
cytokine down-modulated by all the adjuvants tested (Table 1).
In conclusion, o/w squalene and CAF01 promoted the 
antigen-specific CD4+ T cell proliferative response, which shifted 
to a Th1/Th17 response in the presence of CAF01, and to a mixed 
Th1/Th2 response with o/w squalene. Cytokine production was 
not significantly stimulated by alum and CpG adjuvants, that in 
turn downregulated the Th2-biased cytokine response elicited 
by immunization with H56 antigen alone. Taken together, these 
results show the fundamental role of the adjuvant in the vaccine 
formulation to promote a primary CD4+ T cell response and the 
different modulation of the effector response according to the 
adjuvant used. Therefore, CD4+ T cell priming can be considered 
FigUre 3 | cytokine/chemokine production in splenocyte culture 
supernatants. C57BL/6 mice were subcutaneously immunized with H56 
alone (H56) or combined with different adjuvants (o/w squalene, CAF01, 
alum, and CpG), and spleens were collected 7 days after immunization. 
Cytokine secretion was detected upon 3 days of H56 antigen restimulation 
by Luminex immunoassay. Values, expressed as picograms per milliliter, are 
reported as the arithmetic mean ± SD of H56-stimulated minus the 
respective unstimulated samples, of five animals per group.
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an important early biomarker of different classes of adjuvant 
molecules.
Primary B cell response and early 
antibody secretion
In the extra-follicular reaction, some antigen-primed B cells 
differentiate in short-lived PCs producing low affinity antibod-
ies, detectable in serum at low concentration a few days after 
immunization (16, 18). Therefore we assessed the induction of 
short-lived PCs within draining lymph nodes and quantified 
the amount of H56-specific IgG and IgG subclasses, in order 
to define the influence of different adjuvants on the induc-
tion of the early primary humoral response. Twelve days after 
priming, the development of IgD− CD138+ B220int short-lived 
PCs was detected in lymph nodes of mice immunized with 
H56 combined with o/w squalene, alum, or CpG (P ≤  0.05 
versus mice immunized with H56 alone), while the presence 
of CAF01 did not increase the amount of short-lived PCs 
(Figure 4).
A week after priming, the early H56-specific serum IgG 
response was elicited by formulations containing o/w squalene 
or CpG (GMT 100), but not with CAF01, alum, or antigen alone 
(GMT <20) (Figure 5A). A further and consistent increase was 
detected at day 12, especially in groups immunized with H56 
combined with o/w squalene (GMT 95,000) and CpG (GMT 
47,000) with respect to mice immunized with H56 antigen alone 
(GMT 2,030, P ≤ 0.05). The presence of alum did not significantly 
increase the antibody response (GMT 8,900) compared to antigen 
alone, while the response was very low with CAF01 (GMT 740) 
(Figure 5A).
Immunization with H56 alone or combined with o/w squalene 
or alum elicited a prevalence of IgG1 subclass, indicative of a Th2-
biased response, while the IgG1/IgG2c ratio observed with both 
CpG and CAF01 clearly indicated the strong induction of IgG2c 
subclass, indicative of a Th1 cell profile (Figure 5B).
The analysis of the early antibody response, which correlates 
with the induction of short-lived PCs observed in lymph nodes 
(Figure 4), reflects the different modes of action of the analyzed 
molecules. Compounds, such as o/w squalene and CpG, are 
extremely rapid in the stimulation of the early humoral response, 
probably due to a rapid contact between the antigen and the 
immune system, while alum and CAF01, both known to entrap 
the antigen slowing down its release, induce a weaker early 
humoral response, 12 days after priming.
The germinal center reaction
The induction of the GC reaction is considered an important 
biomarker of humoral memory response (39), and Tfh cells 
have emerged as critical for GC formation (17, 40) and for 
the subsequent generation of plasma cells and memory B cells 
(16). Tfh and GC-B cell responses were therefore analyzed after 
immunization with the different vaccine formulations by assess-
ing the expression of functional markers on cells collected from 
draining lymph nodes. The amount of tetramer-binding CD4+ 
T cells expressing PD-1high CXCR5high Bcl-6high (Tfh) cells was 
determined 7 days after primary immunization (Figure 6), while 
B220+ GL-7+ CD95+ GC-B cells were assessed 7 and 12 days after 
FigUre 4 | Plasma cells generation in draining lymph nodes. C57BL/6 
mice were subcutaneously immunized with H56 alone (H56) or combined 
with different adjuvants (o/w squalene, CAF01, alum, and CpG), and the 
induction of short-lived plasma cells was analyzed in dLN, 12 days after 
immunization. Values are reported as number of CD3− IgD− CD138+ B220int 
plasma cells detected in the organ. Bars indicate the mean ± SD of five mice 
per group; data are representative of two independent experiments. Mann–
Whitney test with Bonferroni correction for multiple pairwise comparisons 
was used for assessing statistical difference between each group immunized 
with adjuvant and the H56-immunized group. Kruskal–Wallis test, followed by 
Dunn’s post test for multiple comparisons, was used to assess the statistical 
difference between groups immunized with different adjuvants (*P ≤ 0.05).
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FigUre 5 | early antigen-specific igg response. C57BL/6 mice were subcutaneously immunized with H56 alone (H56) or combined with different adjuvants 
(o/w squalene, CAF01, alum, and CpG), and humoral response was analyzed in blood (a) H56-specific IgG serum response detected by ELISA on sera collected 7 
and 12 days after SC immunization. Antibody titers were expressed as the reciprocal of the highest dilution with an OD value ≥0.2 after background subtraction. 
Values are reported as GMT ± SD of five to eight mice per group, from two independent experiments. Mann–Whitney test, with Bonferroni correction for multiple 
pairwise comparisons, was used for assessing the statistical difference between each group immunized with adjuvant and the H56-immunized group. Kruskal–Wallis 
test, followed by Dunn’s post test for multiple comparisons, was used to assess the statistical difference between groups immunized with different adjuvants 
(*P ≤ 0.05). (B) Ratio of H56-specific IgG1 and IgG2c subclasses assessed in serum of each animal. Data are reported as mean ± SEM for each group.
immunization (Figure 7). The intracellular expression of Bcl-6, 
that is a master regulator for both the GC B cell program (41) 
and Tfh cell lineage (42), was evaluated in both cell populations. 
A  significant amount of Tfh cells was observed in all vaccine 
formulations containing adjuvants compared to H56 alone, 
7 days after priming (Figure 6). The amount of Ag-specific Tfh 
cells induced by CpG was much lower compared to the other 
vaccine formulations, especially compared to CAF01 (Figure 6C; 
P ≤ 0.05). At the same time point, the GC-B cell response was still 
not induced (Figure 7A), but at day 12, GC-B cells were signifi-
cantly elicited by formulations containing adjuvants compared to 
antigen alone (Figures 7B,C). A significant difference in terms 
of GC-B cells was observed between CAF01 and CpG adjuvants 
(Figure 7C).
Altogether, these data show that the presence of adjuvants in 
the vaccine formulation is crucial for the induction of the GC 
reaction. Nevertheless, the magnitude of the response is deeply 
influenced by the adjuvant used.
DiscUssiOn
This study focuses on the characterization of primary T and B-cell 
immune responses upon parenteral priming with different adju-
vants combined with the same vaccine antigen. Adjuvants used 
included a squalene-based oil-in-water emulsion, the liposome 
system CAF01, aluminum hydroxide, and CpG ODN 1826. By 
profiling the response after primary immunization, it was pos-
sible to highlight the different priming properties of the tested 
adjuvants (Table 2).
A clear increase of antigen-specific CD4+ T cells within 
draining lymph nodes was observed following primary immu-
nization with formulations containing CAF01 and o/w squalene 
adjuvants, but not alum and CpG (Table 2). The cytokine profile 
showed a different effector function of antigen-specific CD4+ 
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T-cells induced by different adjuvant formulations. CAF01 was 
the strongest adjuvant capable of stimulating cytokine secretion, 
with a well-defined Th1 and Th17 profile, as previously observed 
following repeated immunizations (14, 31, 43). O/w squalene 
elicited the release of TNF-α, IFN-γ, and IL-4/IL-13 indicative 
of a mixed Th1/Th2 response (Table 2). This is in line with the 
response observed following repeated immunization with the 
squalene-based o/w emulsions MF59®, which primarily induces 
a humoral response with a mixed Th1/Th2 skewing of T helper 
cells (14, 44). H56 antigen alone stimulated a Th2-biased cytokine 
profile, which was down-modulated by the addition of the tested 
adjuvants. While CAF01 primed for an enhanced antigen-specific 
cellular immune response, o/w squalene and CpG elicited a rapid 
and significant humoral immune response. Indeed, o/w squalene 
and CpG stimulated the induction of short-lived PCs within 
draining lymph nodes, which correlated with early H56-specific 
serum IgG antibodies, 12 days after priming (Table 2). On the 
contrary, immunization with antigen alone or mixed with CAF01 
was much less efficient in generating the B cell response at this 
early time point as observed both in terms of PCs and antibodies. 
However, high titers (GMT 20,000) have been reached 4 weeks 
after primary immunization with CAF01 (unpublished data), 
thus suggesting a slower induction of humoral response, or the 
stimulation of a late antibody response, probably mediated by the 
GC-B cells that have been clearly observed with CAF01.
In a vaccination perspective, it is important to elicit the GC 
reaction, with the follicle-localized GC-B cells capable of gener-
ating high-affinity antibody-secreting PCs and memory B cells 
(39), both critical for immune protection and recall responses. 
Tested adjuvants, but not antigen alone, promoted the GC 
reaction with different magnitude. CAF01 elicited the strong-
est induction of Ag-specific Tfh (PD-1+ CXCR5+ Bcl-6+) and 
GC-B (B220+ GL-7+ CD95+) cells, which most likely explains the 
delayed humoral response observed with this adjuvant (14, 45). 
FigUre 6 | Tfh cells induction. Mice were subcutaneously immunized with H56 alone (H56) or combined with different adjuvants (o/w squalene, CAF01, alum, 
and CpG), and draining lymph nodes were collected 7 days after immunization. (a) Analysis of the expression of CXCR5 and PD-1 among tetramer-binding CD4+ T 
cells, for identifying Tfh cells. The intracellular expression of Bcl-6, within CXCR5+ PD-1+ cells, is reported as histogram. Data are shown from a single animal 
representative of the group. (B,c) Frequencies of Tfh cells, with respect to tetramer+ CD4+ T cells (B) and absolute numbers of Tfh cells per dLN (c), elicited by 
different vaccine formulations reported as mean ± SD of five mice per group; data are representative of two independent experiments. Mann–Whitney test, with 
Bonferroni correction for multiple pairwise comparisons, was used for assessing the statistical difference between each group immunized with adjuvant and the 
H56-immunized group. Kruskal–Wallis test, followed by Dunn’s post test for multiple comparisons, was used to assess the statistical difference between groups 
immunized with different adjuvants (*P ≤ 0.05).
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FigUre 7 | germinal center B cells induction. Mice were subcutaneously immunized with H56 alone (H56) or combined with different adjuvants (o/w 
squalene, CAF01, alum, and CpG), and draining lymph nodes were collected 7 and 12 days after immunization. (a) Germinal center B cells, identified as GL-7+ 
CD95+ among B220+ B cells in iliac lymph nodes 7 and 12 days after immunization. Intracellular Bcl-6 expression within germinal center B cells was analyzed 
and reported as histogram. Data are shown from a single animal representative of the group. (B,c) Frequencies of GC-B cells, with respect to B220+ B cells 
(B) and absolute numbers of GC-B cells per dLN (c) reported as mean ± SD of five mice per group. Mann–Whitney test, with Bonferroni correction for multiple 
pairwise comparisons, was used for assessing the statistical difference between each group immunized with adjuvant and the H56-immunized group. 
Kruskal–Wallis test, followed by Dunn’s post test for multiple comparisons, was used to assess the statistical difference between groups immunized with different 
adjuvants (*P ≤ 0.05).
TaBle 2 | evaluation of early adjuvant activity after primary immunization.a
adjuvants immune response
T cell responseb B cell responsec
ag-specific cD4+ T cell  
response
Th subtype ag-specific Tfh  
cells
early ag-specific  
ab response
short-lived  
Pcs
gc-B  
cells
Th1 Th2 Th17
o/w squalene ++ + + − + +++ ++ ++
Alum − − − − +++ − + ++
CAF01 +++ +++ − +++ +++ − − +++
CpG − − − − + +++ + +
aEvaluation of the adjuvant activity: +++, excellent; ++, very good; +, good; –, no response.
bT cell response assessed 7 days after priming, in draining lymph nodes (Ag-specific CD4+ T cell response and Ag-specific Tfh cells) and in the spleen (Th subtype). Ag-specific Th 
cells were detected with Ag85B-complexed MHC II tetramers; Th subtype was based on Ag-specific cytokine production.
cB cell response assessed 12 days after priming, in blood (early Ag-specific Ab response) and draining lymph nodes (short-lived PCs and GC-B cells); PCs, plasma cells; GC, 
germinal center.
11
Ciabattini et al. Adjuvant Activity after Primary Immunization
Frontiers in Immunology | www.frontiersin.org October 2016 | Volume 7 | Article 427
Also o/w squalene and alum promoted the GC reaction, while 
CpG induced a mild reaction (Table 2). However, CpG induced 
a rapid and strong humoral response, in line with what described 
since the first studies on the adjuvanticity of this compound 
(46). The observed humoral response elicited by CpG in the 
absence of a significant primary CD4+ T cell response suggests 
a possible T-independent activation of the B cell response. This 
could be due to the direct stimulation of TLRs constitutively 
expressed on naïve B cells in mice (47). In conditions of limited 
B cell receptor stimulation or T-cell help, TLRs might provide 
an additional stimulus to responding B cells that also regulates 
isotype switch (47).
Taken together, the analysis of the early adaptive immune 
response allows profiling the features of an adjuvant at the 
beginning of the vaccine-specific immune response. Of course, 
these data obtained by a single immunization – not followed 
by a boost – do not allow comparison of adjuvant efficacy in a 
vaccine perspective but rather show that different adjuvants 
yield different responses that can be profiled early after primary 
immunization. This profiling can be instrumental for the rational 
design of advanced prime–boost immunization for the develop-
ment  of future vaccines. Indeed, understanding the modes of 
action of adjuvant molecules will allow the development of strat-
egies of vaccination based on a rational design of heterologous 
prime–boost formulations, or on combinations of adjuvants. 
Specific adjuvants can be selected for their priming properties, 
and strategically boosted with other vaccine formulations, in 
order to optimize the vaccine antigen-specific immune response. 
The present analysis clearly shows the possibility of identifying 
the key properties of adjuvants since the first immunization based 
on serology and cellular immunology approaches. This offers the 
unique advantage of selecting the optimal priming strategy based 
on the immunological signature of a vaccine formulation that can 
be rationally combined with heterologous booster approaches.
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